Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LNTH 1095

Next Previous
Drug Profile

LNTH 1095

Alternative Names: 1095; 123I-MIP-1095; [131I] MIP-1095; I-131-1095; I-131-MIP-1466; I131-MIP-1095; LNTH-1095; MIP-1095; MIP-1095 I123; MIP-1095 I131; MIP-1466

Latest Information Update: 02 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer Progenics Pharmaceuticals
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 13 Sep 2024 Efficacy and adverse events data from the phase II ARROW trial in Prostate cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 25 Aug 2023 Adhoc client query: approved name updated (LNTH 1095); synonyms added (MIP 1095 I-131); DC addition request sent (radioisotopes); thes request sent to map the terms.Org role updated.
  • 08 Dec 2022 LNTH 1095 is still in phase II trials for Prostate cancer (Combination therapy, Hormone refractory, Late-stage disease, Metastatic disease) in USA and Canada (NCT03939689) (Lantheus pipeline, December 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top